Introduction. Over the past 25 years, the incidence of fungal infection has increased at an alarming rate across the world, due to a significant growth in the prevalence of resistance to antifungal agents. Azole derivatives are of increased interest in the development of new antifungal products with the ability to overcome drug resistance, reduce toxicity and improve pharmacokinetic profiles. Material and methods. According to the State Nomenclature of Medicinal Products registered in the Republic of Moldova and the National Price Catalogue of Medicinal Products Manufacturers, we selected and analyzed by ATC code azole-derived medicinal products in the Republic of Moldova. Results. According to ATC, azole derivatives are included in group D01AC (imidazole and triazole derivatives) – 19 TN and J02AC (triazole derivatives) – 65 TN. The market leader in Moldova is Fluconazole 58 (69%), followed by Ketoconazole 8 (10%), Clotrimazole 5 (6%), Itraconazole 5 (6%), Bifonazole 2 (3%), Fenticonazole, Isoconazole, Sertaconazole, Voriconazole, Posaconasole 1 each (1%). 18 TN (21%) are autochthonous (Fluconazole 15, Clotrimazole, Ketoconazole, Sertaconazole each 1). The leading DRC holder is SC Balkan Pharmaceuticals SRL with 10 TN. Importing countries with a high rate are: India (24%), Turkey (12%), Romania (11%). By pharmaceutical form the most prevalent are Capsules (44%), Tablets (18%), Cream (16%). Conclusions. There are 84 Trade Names registered in the Republic of Moldova. The leader is Fluconazole by 58, but many strains are resistant to it, so new antifungal agents with fewer adverse effects are needed, which reduce resistance, toxicity, improve bioavailability and antifungal spectrum.